Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, July 26 '25)

Image
By G.M.

 


    Biochem Biophys Res Commun

  1. KUSUMOTO T, Yotsukura M, Asakura T, Namkoong H, et al
    Induced lung epithelial-like cells derived by direct reprogramming rescue influenza virus-induced lung injury in mice.
    Biochem Biophys Res Commun. 2025;778:152384.
    PubMed         Abstract available


    J Infect

  2. SAITO R, Chon I, Sato I, Kawashima T, et al
    Impact of polymerase acidic subunit (PA) substitutions on fever and symptoms in pediatric influenza A patients treated with baloxavir: A pooled four-season analysis.
    J Infect. 2025;91:106555.
    PubMed         Abstract available


    J Infect Dis

  3. SIMOES EAF, Suss RJ, Raje DV
    Human Metapneumovirus, Respiratory Syncytial Virus and Influenza Associated Pneumonia Hospitalizations in Colorado Adults Aged Over 50 Years: 2016-2023.
    J Infect Dis. 2025 Jul 21:jiaf381. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  4. MANNSVERK S, Villamil Giraldo AM, Kasson PM
    Influenza viral infection at the plasma membrane is restricted by lipid composition.
    J Virol. 2025 Jul 24:e0110525. doi: 10.1128/jvi.01105.
    PubMed         Abstract available

  5. SIMONICH CAL, McMahon TE, Ju X, Yu TC, et al
    RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.
    J Virol. 2025;99:e0053125.
    PubMed         Abstract available

  6. ZHANG J, Li M, Cheng J, Wang Y, et al
    CypA inhibits respiratory syncytial virus (RSV) replication by suppressing glycolysis through the downregulation of PKM2 expression.
    J Virol. 2025;99:e0007425.
    PubMed         Abstract available

  7. POWELL BH, Witwer KW, Meffert MK
    Cellular miRNAs and viruses: trends in miRNA sequestering and target de-repression.
    J Virol. 2025 Jun 18:e0091425. doi: 10.1128/jvi.00914.
    PubMed         Abstract available

  8. CHEN Y, Shi Y, Zuo X, Dong X, et al
    UNC0638 inhibits SARS-CoV-2 entry by blocking cathepsin L maturation.
    J Virol. 2025 Jun 18:e0074125. doi: 10.1128/jvi.00741.
    PubMed         Abstract available

  9. HARRIS C, Kapingidza AB, San JE, Christopher J, et al
    Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.
    J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465.
    PubMed         Abstract available

  10. LOKUGAMAGE KG, Zhou Y, Alvarado RE, Plante JA, et al
    Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection.
    J Virol. 2025 Jun 12:e0209124. doi: 10.1128/jvi.02091.
    PubMed         Abstract available

  11. COTTIGNIES-CALAMARTE A, Marteau F, He F, Belouzard S, et al
    Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.
    J Virol. 2025 Jun 12:e0039425. doi: 10.1128/jvi.00394.
    PubMed         Abstract available

  12. MORGAN AL, Vu MN, Zhou Y, Lokugamage KG, et al
    The furin cleavage site is required for pathogenesis, but not transmission, of SARS-CoV-2.
    J Virol. 2025 Jun 10:e0046725. doi: 10.1128/jvi.00467.
    PubMed         Abstract available

  13. FOSTER CSP, Walker GJ, Jean T, Wong M, et al
    Long-term serial passaging of SARS-CoV-2 reveals signatures of convergent evolution.
    J Virol. 2025 Jun 9:e0036325. doi: 10.1128/jvi.00363.
    PubMed         Abstract available

  14. NGUYEN D, Laidlaw SM, Dong X, Wand M, et al
    SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management.
    J Virol. 2025 Jun 4:e0051925. doi: 10.1128/jvi.00519.
    PubMed         Abstract available

  15. KALIN JH, Yin Y, Tran MT, Piassek M, et al
    Discovery of a non-nucleoside inhibitor that binds to a novel site in the palm domain of the respiratory syncytial virus RNA-dependent RNA polymerase.
    J Virol. 2025;99:e0017825.
    PubMed         Abstract available


    Lancet


  16. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    PubMed         Abstract available


    PLoS Comput Biol

  17. GONG R, Feng Z, Zhang Y
    Using homologous network to identify reassortment risk in H5Nx avian influenza viruses.
    PLoS Comput Biol. 2025;21:e1013301.
    PubMed         Abstract available

  18. KEITHLEY J, Choudhuri A, Adhikari B, Pemmaraju SV, et al
    Analyzing greedy vaccine allocation algorithms for metapopulation disease models.
    PLoS Comput Biol. 2025;21:e1012539.
    PubMed         Abstract available

  19. KOLAR MR, Kobzarenko V, Mitra D
    Efficient discovery of frequently co-occurring mutations in a sequence database with matrix factorization.
    PLoS Comput Biol. 2025;21:e1012391.
    PubMed         Abstract available


    PLoS Med

  20. KNOWLTON KU, Siegel LK, Barkauskas CE, Bhagani S, et al
    Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.
    PLoS Med. 2025;22:e1004616.
    PubMed         Abstract available


    PLoS One

  21. MONROY-IGLESIAS MJ, Thavarajah R, Beckmann K, Josephs DH, et al
    Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank.
    PLoS One. 2025;20:e0328232.
    PubMed         Abstract available

  22. BISHOP F, Howick J, Vennik J, Bostock J, et al
    Feasibility trial of a new digital training package to enhance primary care practitioners' communication of clinical empathy and realistic optimism.
    PLoS One. 2025;20:e0324649.
    PubMed         Abstract available

  23. KANG ZT, Yen PT, Cheong SA
    Indicator from the graph Laplacian of stock market time series cross-sections can precisely determine the durations of market crashes.
    PLoS One. 2025;20:e0327391.
    PubMed         Abstract available

  24. WILLIAMS R, Bolton T, Jenkins D, Mizani MA, et al
    The challenges of replication: A worked example of methods reproducibility using electronic health record data.
    PLoS One. 2025;20:e0326335.
    PubMed         Abstract available

  25. DORNEY J, Ebna Mannan I, Malicki C, Wisk LE, et al
    Impact of SARS-CoV-2 on healthcare and essential workers: A longitudinal study of PROMIS-29 outcomes.
    PLoS One. 2025;20:e0324755.
    PubMed         Abstract available

  26. ROMAN-MONTES CM, Tamez-Torres KM, Guaracha-Basanez GA, Ordinola-Navarro A, et al
    Factors associated with indeterminate QuantiFERON-TB Gold Plus Test results during the COVID-19 pandemic.
    PLoS One. 2025;20:e0326615.
    PubMed         Abstract available

  27. THITY NT, Rahman A, Dulmini A, Yasmin MN, et al
    An illustration of multi-class roc analysis for predicting internet addiction among university students.
    PLoS One. 2025;20:e0325855.
    PubMed         Abstract available

  28. MA KPK, Stober T, Gottlieb M, Geyer RE, et al
    Participant engagement in a national longitudinal study of COVID-19: Insights from the INSPIRE study.
    PLoS One. 2025;20:e0325948.
    PubMed         Abstract available

  29. KRAPEZ U, Kuhar U, Senica P, Slavec B, et al
    Different SARS-CoV-2 variants inhibited by RRM designed peptide.
    PLoS One. 2025;20:e0327582.
    PubMed         Abstract available

  30. QI J, Huang D, Chen Y, Huang D, et al
    From the frontlines to the future: Anti-epidemic volunteer experience and career rewards for doctors.
    PLoS One. 2025;20:e0328044.
    PubMed         Abstract available

  31. POLLETT SD, Colombo RE, Richard SA, Lalani T, et al
    The infectious diseases clinical research program acute respiratory infection repository protocol: Opportunities to understand current and future epidemics.
    PLoS One. 2025;20:e0317065.
    PubMed         Abstract available

  32. GOTTLIEB M, Spatz ES, Yu H, Ebna Mannan I, et al
    Effects of long COVID on healthcare utilization.
    PLoS One. 2025;20:e0327218.
    PubMed         Abstract available

  33. DARAGHMEH DN, Salah A, Hamdan N, Zamareh A, et al
    Attitudes, beliefs, and practices regarding complementary and alternative medicine use: Influenza vaccine intake.
    PLoS One. 2025;20:e0320412.
    PubMed         Abstract available

  34. ROBERTI J, Carmiol-Rodriguez P, Chan-Liang E, Aguilar-Vidrio OA, et al
    Enhancing tuberculosis treatment support: A thematic analysis of interactive messages in a digital adherence technology trial to identify needs, challenges, and strategies for improvement.
    PLoS One. 2025;20:e0326492.
    PubMed         Abstract available

  35. TAVARES IC, Maria Guerreiro da Silva D, Ferreira Monteiro W, Janara Veras Lima K, et al
    Therapeutic itineraries and testimonies of COVID-19 patients in Manaus, the epicenter of the pandemic in the Brazilian Amazon.
    PLoS One. 2025;20:e0327127.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  36. MENON T, McQuilten HA, Samir J, Nguyen THO, et al
    Central memory T cells with key TCR repertoires and gene expression profiles dominate influenza CD8+ T cell pools across the human lifespan.
    Proc Natl Acad Sci U S A. 2025;122:e2501167122.
    PubMed         Abstract available

  37. LEE AS
    Stress-induced translocation of the endoplasmic reticulum chaperone GRP78/BiP and its impact on human disease and therapy.
    Proc Natl Acad Sci U S A. 2025;122:e2412246122.
    PubMed         Abstract available


    Vaccine

  38. PICKERING H, Valli E, Carlock MA, Cappelletti M, et al
    Influenza strain-specific T cell responses longitudinally post-vaccination with FluZone.
    Vaccine. 2025;62:127506.
    PubMed         Abstract available


    Virus Res

  39. SANZ-MUNOZ I, Martin-Toribio A, Garcia-Concejo A, Arroyo-Hernantes I, et al
    A 15-year study of neuraminidase mutations and the increasing of S247N mutation in Spain.
    Virus Res. 2025;358:199599.
    PubMed         Abstract available

  40. CHEN Z, Cai M, Chai L, Li X, et al
    Anti-influenza Activity of Blumea Balsamifera (L.) DC. Extract: In Vitro and In Vivo Evaluation Against Multiple Influenza Virus Strains.
    Virus Res. 2025 Jul 20:199606. doi: 10.1016/j.virusres.2025.199606.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »